Zylox-Tonbridge Warns of 'Significant' FY21 Loss Despite Sixfold Jump in Revenue; Shares Fall 7%

MT Newswires · 02/14/2022 15:16

02:13 AM EST, 02/14/2022 (MT Newswires) -- Zylox-Tonbridge Medical Technology (HKG:2190) will not swing to profit for the year ended Dec. 31, 2021 despite an estimated 545% surge in revenue and 73% jump in gross profit margin.

The company forecasts its 2021 revenue to reach 178 million yuan ($28 million), a more than sixfold increase from 27.6 million yuan in the prior year, according to a Monday disclosure.

The medical device maker attributed the expected revenue growth to robust sales of key products and the market launch of eight new products in China that obtained regulatory approvals last year.

The surge in profit margin, meanwhile, was driven by the decline in raw material price due to increased procurement volume, as well as its improved production efficiency amid technology upgrades.

Nevertheless, Zylox-Tonbridge will continue to incur "significant losses" in 2021 amid its sustained heavy investments in research and development activities.

The stock declined nearly 7% in recent trade.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.